So my musings continue on the endocannabinoid system and deficiency of cannabinoids causing discomforts and disorders.  Many people are suffering from different pain disorders.  But it seems that there is a common thread of relief.  Cannabis Sativa "L", hemp derived cannabidiol is that common thread.  I am constantly amazed how CBD relieves pain.  I have created a line of Hemp Relief Roll-On's that address specific discomforts as CBD appears to be the "common thread" for all pain disorders.  Besides hemp derived CBD, each roll-on contains specific Young Living essential oils for specific discomforts.  

There are many clinical studies underway, but one that recently caught my eye: "In a small study 28 fibromyalgia patients took cannabis and were compared with a control group of patients who did not. Two hours after cannabis use, there was a reported ‘reduction of pain and stiffness, enhancement of relaxation and an increase in somnolence and feeling of well-being’. Another recent survey comparing the efficacy of cannabis with pharmaceutical drugs generally used for fibromyalgia found that cannabis came out best compared to the prescription alternatives." 

I have conducted my own test on my husband, John, who kept experiencing red swollen, painful finger and toe.  Other than these painful flareups John is in excellent health and doesn't take any pharmaceuticals.  We changed his diet,  many times for over a year.  We finally isolated it to nightshades, specifically peppers, which he loves in ethnic foods.  So totally eliminating spicy peppers we managed the flare ups.  But  as soon as he would consume his favorite Mexican food, the swelling and pain would return.  Applying CBD topically totally took care of the pain and swelling, but would return if he ate spicy pepper dishes two days in a row.  So, I seized the moment to test my theory that his pain was due to a deficiency of cannabinoids within his endocannabinoid system.  John began taking  a dose each morning and if the pain/swelling came on, he took more, and he enjoyed his favorite Mexican and Thai food weekly, (several times).  After about the first month, the need to consume CBD due to pain/swelling was gone.  He continues to take his morning dose, supplementing his endocannabinoid system and has not had an arthritic flare up for over 6 months.  I am so happy I have found CBD.  
It is my dream that everyone enjoy their lives pain free.  
​

I'm not alone in my theory that our disorders and discomforts may be related to a CBD deficiency.  Dr. Ethan Russo, believes many disorders, share a lack of what has become known as ‘endocannabinoid tone’ – i.e. how well the ECS performs its core role of keeping balance in the body. 

In a recent interview Dr Ethan Russo a pioneering scientist in the endocannabinoid field, describes the ECS as a buffer ‘something that will work both ways as need be. So, for example, in the endocannabinoid system one of its main roles in the brain is to regulate neurotransmitter function and again, if there’s too much of one kind of neurotransmitter it will bring it down, if there’s too little it will bring it up’.
Another example of how the ECS restores balance is with neuropathic pain – a condition associated with MS, HIV and diabetes, but notoriously difficult to treat with pharmaceutical drugs. So the ECS acts as a dimmer switch, upregulating or downregulating when necessary, a principle that can be applied to all systems of the body.  
But what happens if the Endocannabinoid System isn’t functioning correctly. According to Dr Russo, ‘If you don’t have enough endocannabinoids you have pain where there shouldn’t be pain. You would be sick, meaning nauseated. You would have a lowered seizure threshold. And just a whole litany of other problems’. Russo sees a pattern between these symptoms and a number of conditions that until now modern medicine has found difficult to treat, namely migraine, irritable bowel syndrome (IBS) and fibromyalgia. 

Sceptics might believe this to be pure coincidence, but studies have already shown how the production of the endocannabinoid anandamide might have some bearing on the situation. Russo states ‘available data confirm that the target organs (brain, gut, musculoskeletal system) seem to express lower than normal levels of anandamide, thus providing credence for the concept that they would benefit from treatments that would upregulate the ECS back to normal levels’.
Russo’s named it ‘Clinical Endocannabinoid Deficiency’ (CED) and is based on the concept ‘that many brain disorders are associated with neurotransmitter deficiencies, Alzheimer’s disease, parkinsonian syndromes, depression, and that a comparable deficiency in endocannabinoid levels might be manifest similarly in certain disorders that display predictable clinical features’ as a result of this deficiency.
He believes that supplementing an impaired ECS with plant cannabinoids will bring it back to optimum function, thus provoking an improvement in any many conditions.  Here-Here!